Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Launch date
Employees
Market cap
€4.8b
Enterprise valuation
€4.6b (Public information from Sep 2024)
Share price
$89.33 BPMC
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 794m | 180m | 204m | 249m | 496m | 687m | 936m |
% growth | 1093 % | (77 %) | 13 % | 22 % | 99 % | 39 % | 36 % |
EBITDA | 309m | (634m) | (529m) | (470m) | (227m) | (93.1m) | 98.5m |
% EBITDA margin | 39 % | (352 %) | (259 %) | (189 %) | (46 %) | (14 %) | 11 % |
Profit | 314m | (644m) | (558m) | (507m) | (98.2m) | (117m) | 51.9m |
% profit margin | 40 % | (358 %) | (273 %) | (203 %) | (20 %) | (17 %) | 6 % |
EV / revenue | 6.8x | 32.4x | 8.9x | 20.6x | 10.6x | 7.7x | 5.5x |
EV / EBITDA | 17.4x | -9.2x | -3.4x | -10.9x | -23.3x | -56.7x | 52.0x |
R&D budget | 327m | 601m | 477m | 428m | - | - | - |
R&D % of revenue | 41 % | 334 % | 234 % | 172 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$40.0m | Series A | ||
N/A | Early VC | ||
$25.0m | Series B | ||
$50.0m | Series C | ||
N/A | $147m Valuation: $398m | IPO | |
N/A | $135m | Post IPO Equity | |
N/A | $216m | Post IPO Equity | |
N/A | $326m | Post IPO Equity | |
N/A | $327m | Post IPO Equity | |
$1.3b Valuation: $1.3b 6.9x EV/LTM Revenues -2.0x EV/LTM EBITDA | Post IPO Equity | ||
Total Funding | €105m |
Recent News about Blueprint Medicines
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Blueprint Medicines
EditACQUISITION by Blueprint Medicines Nov 2021